MaxCyte, Inc. – NASDAQ:MXCT
Founder-led company
MaxCyte stock price today
$1.41
-2.71
-65.86%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
MaxCyte stock price monthly change
-8.02%
month
MaxCyte stock price quarterly change
-8.02%
quarter
MaxCyte stock price yearly change
-7.61%
year
MaxCyte key metrics
Market Cap | 419.29M |
Enterprise value | 510.52M |
P/E | -20.62 |
EV/Sales | 11.53 |
EV/EBITDA | -25.13 |
Price/Sales | 11.42 |
Price/Book | 1.99 |
PEG ratio | 2.16 |
EPS | -0.35 |
Revenue | 44.05M |
EBITDA | -43.02M |
Income | -36.56M |
Revenue Q/Q | 32.24% |
Revenue Y/Y | 6.79% |
Profit margin | -53.25% |
Oper. margin | -61.82% |
Gross margin | 88.48% |
EBIT margin | -61.82% |
EBITDA margin | -97.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMaxCyte stock price history
MaxCyte stock forecast
MaxCyte financial statements
| Jun 2023 | 9.04M | -10.51M | -116.25% |
|---|---|---|---|
| Sep 2023 | 8.00M | -11.25M | -140.57% |
| Dec 2023 | 15.66M | -5.27M | -33.68% |
| Mar 2024 | 11.34M | -9.52M | -83.99% |
| Mar 2024 | 11.34M | -9.52M | -83.99% |
|---|---|---|---|
| Sep 2025 | 10.92M | -9.85M | -90.19% |
| Oct 2025 | 11.32M | -11.10M | -98.02% |
| Dec 2025 | 12.23M | -11.10M | -90.74% |
Analysts Price target
Financials & Ratios estimates
| 2024-05-07 | -0.14 | -0.09 |
|---|
| Jun 2023 | 271204100 | 30.22M | 11.14% |
|---|---|---|---|
| Sep 2023 | 266727100 | 33.35M | 12.5% |
| Dec 2023 | 268274000 | 36.10M | 13.46% |
| Mar 2024 | 257930000 | 31.57M | 12.24% |
| Jun 2023 | -10.10M | 26.67M | 156.7K |
|---|---|---|---|
| Sep 2023 | -8.23M | 2.81M | 36.7K |
| Dec 2023 | 981.7K | -4.13M | 493K |
| Mar 2024 | -10.56M | -14.39M | 703K |
MaxCyte alternative data
| Aug 2023 | 125 |
|---|---|
| Sep 2023 | 125 |
| Oct 2023 | 125 |
| Nov 2023 | 125 |
| Dec 2023 | 125 |
| Jan 2024 | 125 |
| Feb 2024 | 125 |
| Mar 2024 | 143 |
| Apr 2024 | 143 |
| May 2024 | 143 |
| Jun 2024 | 143 |
| Jul 2024 | 143 |
MaxCyte other data
60.58%
-6.23%
of MXCT is owned by hedge funds
61.44M
-6.23M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 5000 |
| Mar 2024 | 0 | 5000 |
| Jun 2024 | 100000 | 43333 |
| Jul 2024 | 0 | 36333 |
| Aug 2024 | 0 | 36333 |
| Sep 2024 | 0 | 50689 |
| Oct 2024 | 0 | 50689 |
| Nov 2024 | 0 | 47689 |
| Dec 2024 | 0 | 3000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | JOHNSTON JOHN JOSEPH director | Common Stock | 483 | $2.93 | $1,416 | ||
Option | JOHNSTON JOHN JOSEPH director | Common Stock | 1,121 | $1.64 | $1,840 | ||
Option | JOHNSTON JOHN JOSEPH director | Common Stock | 891 | $2.93 | $2,607 | ||
Sale | JOHNSTON JOHN JOSEPH director | Common Stock | 2,495 | $3.79 | $9,459 | ||
Option | JOHNSTON JOHN JOSEPH director | Stock Option (right to buy) | 483 | $2.93 | $1,416 | ||
Option | JOHNSTON JOHN JOSEPH director | Stock Option (right to buy) | 2,012 | $2.28 | $4,595 | ||
Option | JOHNSTON JOHN JOSEPH director | Common Stock | 505 | $2.93 | $1,478 | ||
Sale | JOHNSTON JOHN JOSEPH director | Common Stock | 505 | $3.7 | $1,869 | ||
Option | JOHNSTON JOHN JOSEPH director | Stock Option (right to buy) | 505 | $2.93 | $1,478 | ||
Option | ERCK STANLEY C director | Common Stock | 47,689 | $0.04 | $1,908 |
| Quarter | Transcript |
|---|---|
| Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 12 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Douglas Arthur Doerfler (1956) Founder, Pres, Chief Executive Officer & Executive Director | $891,460 |
Ms. Amanda Louise Murphy C.F.A. (1977) Chief Financial Officer | $603,990 |
| Dr. J. Stark Thompson Ph.D. (1942) Consultant | $79,500 |
-
What's the price of MaxCyte stock today?
One share of MaxCyte stock can currently be purchased for approximately $1.41.
-
When is MaxCyte's next earnings date?
Unfortunately, MaxCyte's (MXCT) next earnings date is currently unknown.
-
Does MaxCyte pay dividends?
No, MaxCyte does not pay dividends.
-
How much money does MaxCyte make?
MaxCyte has a market capitalization of 419.29M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.72% to 41.29M US dollars. MaxCyte made a loss 37.92M US dollars in net income (profit) last year or -$0.09 on an earnings per share basis.
-
What is MaxCyte's stock symbol?
MaxCyte, Inc. is traded on the NASDAQ under the ticker symbol "MXCT".
-
What is MaxCyte's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of MaxCyte?
Shares of MaxCyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MaxCyte's key executives?
MaxCyte's management team includes the following people:
- Mr. Douglas Arthur Doerfler Founder, Pres, Chief Executive Officer & Executive Director(age: 69, pay: $891,460)
- Ms. Amanda Louise Murphy C.F.A. Chief Financial Officer(age: 48, pay: $603,990)
- Dr. J. Stark Thompson Ph.D. Consultant(age: 83, pay: $79,500)
-
Is MaxCyte founder-led company?
Yes, MaxCyte is a company led by its founder Mr. Douglas Arthur Doerfler.
-
How many employees does MaxCyte have?
As Jul 2024, MaxCyte employs 143 workers.
-
When MaxCyte went public?
MaxCyte, Inc. is publicly traded company for more then 4 years since IPO on 30 Jul 2021.
-
What is MaxCyte's official website?
The official website for MaxCyte is maxcyte.com.
-
Where are MaxCyte's headquarters?
MaxCyte is headquartered at 9713 Key West Avenue, Rockville, MD.
-
How can i contact MaxCyte?
MaxCyte's mailing address is 9713 Key West Avenue, Rockville, MD and company can be reached via phone at +30 19441700.
MaxCyte company profile:
MaxCyte, Inc.
maxcyte.comExchange:
NASDAQ
Full time employees:
143
Industry:
Medical - Devices
Sector:
Healthcare
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
9713 Key West Avenue
Rockville, MD 20850
Rockville, MD 20850
CIK: 0001287098
ISIN: US57777K1060
CUSIP: 57777K106
